FDA approves new osteoporosis drug for postmenopausal women with high fracture risk

The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture).
Read More